{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T01:46:06Z","timestamp":1776908766356,"version":"3.51.2"},"reference-count":41,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,3,25]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>People living with HIV (PLHIV) have a higher risk of developing pulmonary hypertension (PH) with subsequent poorer prognosis. This review aimed to determine the (1) survival outcomes and (2) proportion of emergency department (ED) visits and hospitalisations of PLHIV and PH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review and meta-analysis of observational studies reporting survival outcomes for PLHIV and PH. Electronic databases (Medline, EMBASE, PubMed, Web of Science, Global Index Medicus and Cochrane Library), trial registries and conference proceedings were searched until 22 July 2023. We pooled similar measures of effect, assessed apriori subgroups and used meta-regression to determine mortality and associated variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>5248 studies were identified; 28 studies were included with a total of 5459 PLHIV and PH. The mean survival (95%\u2009CI) of PLHIV and PH was 37.4 months (29.9 to 44.8). Participants alive at 1, 2 and 3 years were 85.8% (74.1% to 95.0%), 75.2% (61.9% to 86.7%) and 61.9% (51.8% to 71.6%), respectively. ED visits and hospitalisation rates were 73.3% (32.5% to 99.9%) and 71.2% (42.4% to 94.2%), respectively. More severe disease, measured by echocardiogram, was associated with poorer prognosis (\u03b2 \u22120.01, 95%\u2009CI \u22120.02 to 0.00, p=0.009). Survival was higher in high-income countries compared with lower-income countries (\u03b2 0.50, 95%\u2009CI 0.28 to 0.73, p&lt;0.001) and in Europe compared with the America (\u03b2 0.56, 95%\u2009CI 0.37 to 0.75, p&lt;0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our study confirms poor prognosis and high healthcare utilisation for PLHIV and PH. Prognosis is associated with country income level, geographic region and PH severity. This highlights the importance of screening in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42023395023.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2024-002318","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T13:10:20Z","timestamp":1712841020000},"page":"e002318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Pulmonary hypertension survival and hospitalisations in people living with HIV: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-0802","authenticated-orcid":false,"given":"Mark","family":"Youssef","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Boutros Salama","sequence":"additional","affiliation":[{"name":"Health Science Education MSc Program, McMaster University, Hamilton, Ontario, Canada"},{"name":"McMaster Okanagan Office of Health and Well-being, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Health, Research, Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Hanna","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Rose","family":"Waniss","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Mbuagbaw","sequence":"additional","affiliation":[{"name":"Department of Health, Research, Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada"},{"name":"Biostatistics Unit, Father Sean O'Sullivan Research Centre, St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"2025083111144832000_11.1.e002318.1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(15)00543-3"},{"key":"2025083111144832000_11.1.e002318.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.032"},{"key":"2025083111144832000_11.1.e002318.3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01904-2018","article-title":"Diagnosis of pulmonary hypertension","volume":"53","author":"Frost","year":"2019","journal-title":"Eur Respir J"},{"key":"2025083111144832000_11.1.e002318.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-015-0078-3","article-title":"HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment","volume":"12","author":"Bigna","year":"2015","journal-title":"AIDS Res Ther"},{"key":"2025083111144832000_11.1.e002318.5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/COH.0000000000000418","article-title":"HIV-associated pulmonary hypertension","volume":"12","author":"Jarrett","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2025083111144832000_11.1.e002318.6","doi-asserted-by":"crossref","unstructured":"Bigna JJ , Nansseu JR , Noubiap JJ . Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis. Sci Rep 2019;9. doi:10.1038\/s41598-019-44300-5","DOI":"10.1038\/s41598-019-44300-5"},{"key":"2025083111144832000_11.1.e002318.7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1871526517666170505122800","article-title":"HAART in HIV\/AIDS treatments: future trends","volume":"18","author":"Lu","year":"2018","journal-title":"Infect Disord Drug Targets"},{"key":"2025083111144832000_11.1.e002318.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011921","article-title":"Prevalence and incidence of pulmonary hypertension among HIV-infected people in Africa: a systematic review and meta-analysis","volume":"6","author":"Bigna","year":"2016","journal-title":"BMJ Open"},{"key":"2025083111144832000_11.1.e002318.9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/eci.12427","article-title":"HIV-associated pulmonary arterial hypertension: from bedside to the future","volume":"45","author":"Correale","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"2025083111144832000_11.1.e002318.10","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331c65e"},{"key":"2025083111144832000_11.1.e002318.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"2025083111144832000_11.1.e002318.12","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181fe7999"},{"key":"2025083111144832000_11.1.e002318.13","unstructured":"Higgins J , Morgan R , Rooney A , et al . Risk of bias in non- eandomized studies - of exposure (ROBINS-E). Launch version. 2023."},{"key":"2025083111144832000_11.1.e002318.14","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183"},{"key":"2025083111144832000_11.1.e002318.15","doi-asserted-by":"crossref","unstructured":"Fantom NJ , Serajuddin U . The world bank\u2019s classification of countries by income. World bank policy research working paper. 2016.","DOI":"10.1596\/1813-9450-7528"},{"key":"2025083111144832000_11.1.e002318.16","unstructured":"World Health Organization (WHO) . Health situation analysis in the African region: atlas of health statistics, 2011. World Health Organization (WHO); 2011."},{"key":"2025083111144832000_11.1.e002318.17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025083111144832000_11.1.e002318.18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"2025083111144832000_11.1.e002318.19","unstructured":"Farishta M , Sankari A . Pulmonary hypertension due to lung disease or hypoxia. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023."},{"key":"2025083111144832000_11.1.e002318.20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update","volume":"53","author":"Vonk Noordegraaf","year":"2019","journal-title":"Eur Respir J"},{"key":"2025083111144832000_11.1.e002318.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.01.023"},{"key":"2025083111144832000_11.1.e002318.22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.rmed.2015.05.022","article-title":"Lung function in pulmonary hypertension","volume":"109","author":"Low","year":"2015","journal-title":"Respir Med"},{"key":"2025083111144832000_11.1.e002318.23","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1093\/eurheartj\/suz205","article-title":"The burden of comorbidities in pulmonary arterial hypertension","volume":"21","author":"Lang","year":"2019","journal-title":"Eur Heart J Suppl"},{"key":"2025083111144832000_11.1.e002318.24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003973","article-title":"Increasing incidence and prevalence of world health organization groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada","volume":"11","author":"Wijeratne","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025083111144832000_11.1.e002318.25","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007187","article-title":"The HIV-1 epidemic: low- to middle-income countries","volume":"2","author":"Shao","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025083111144832000_11.1.e002318.26","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12020","article-title":"Prevalence, incidence, and survival of pulmonary arterial hypertension: a systematic review for the global burden of disease 2020 study","volume":"12","author":"Emmons-Bell","year":"2022","journal-title":"Pulm Circ"},{"key":"2025083111144832000_11.1.e002318.27","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glv128"},{"key":"2025083111144832000_11.1.e002318.28","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019894534","article-title":"High geographic prevalence of pulmonary artery hypertension: associations with Ethnicity, drug use, and altitude","volume":"10","author":"Dubroff","year":"2020","journal-title":"Pulm Circ"},{"key":"2025083111144832000_11.1.e002318.29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1164\/rccm.201907-1447OC","article-title":"Genetic admixture and survival in diverse populations with pulmonary arterial hypertension","volume":"201","author":"Karnes","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083111144832000_11.1.e002318.30","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12209","article-title":"Prognosis in hispanic patient population with pulmonary arterial hypertension: an application of common risk stratification models","volume":"13","author":"Fadah","year":"2023","journal-title":"Pulm Circ"},{"key":"2025083111144832000_11.1.e002318.31","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1164\/rccm.201709-1821ST","article-title":"Health disparities in patients with pulmonary arterial hypertension: a blueprint for action. an official American thoracic society statement","volume":"196","author":"Talwar","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083111144832000_11.1.e002318.32","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00638-2020","article-title":"Socioeconomic status and survival in patients with pulmonary hypertension","volume":"6","author":"Ong","year":"2020","journal-title":"ERJ Open Res"},{"key":"2025083111144832000_11.1.e002318.33","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002027"},{"key":"2025083111144832000_11.1.e002318.34","first-page":"195","article-title":"Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance","volume":"30","author":"Dresdale","year":"1954","journal-title":"Bull N Y Acad Med"},{"key":"2025083111144832000_11.1.e002318.35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/01.aids.0000327514.60879.47","article-title":"Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era","volume":"22 Suppl 3","author":"Opravil","year":"2008","journal-title":"AIDS"},{"key":"2025083111144832000_11.1.e002318.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1668OC"},{"key":"2025083111144832000_11.1.e002318.37","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.3.9117037"},{"key":"2025083111144832000_11.1.e002318.38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.maturitas.2017.11.012","article-title":"Cardiovascular disease in women living with HIV: a narrative review","volume":"108","author":"Solomon","year":"2018","journal-title":"Maturitas"},{"key":"2025083111144832000_11.1.e002318.39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacbts.2021.10.017","article-title":"HIV, combination antiretroviral therapy, and vascular diseases in men and women","volume":"7","author":"Kovacs","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"2025083111144832000_11.1.e002318.40","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019899775"},{"key":"2025083111144832000_11.1.e002318.41","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328354f5a1"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2024-002318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T18:14:54Z","timestamp":1756664094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2024-002318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjresp-2024-002318"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2024-002318","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}